Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | RARA | P10276 | 2/20 | 0.45 |
| ▸ | RARB | P10826 | 2/20 | 0.45 |
| ▸ | RARG | P13631 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | DCK | P27707 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902419 | 0.86 | RARA (0.47) | HRH3SMN1; SMN2RARARARBRARG | |
| SCHEMBL4034919 | 0.82 | RARA (0.49) | HRH3SMN1; SMN2RARARARBRARG | |
| SCHEMBL1436257 | 0.82 | HRH3 (0.46) | HRH3SMN1; SMN2RARARARBRARG | |
| SCHEMBL2091544 | 0.82 | HRH3 (0.46) | HRH3SMN1; SMN2RARARARBRARG | |
| SCHEMBL1732966 | 0.82 | HRH3 (0.46) | HRH3SMN1; SMN2RARARARBRARG | |
| SCHEMBL19938082 | 0.81 | RARA (0.48) | HRH3SMN1; SMN2RARARARBRARG | |
| SCHEMBL1436076 | 0.79 | RARA (0.50) | HRH3SMN1; SMN2RARARARBRARG | |
| SCHEMBL12116509 | 0.79 | HRH3 (0.54) | HRH3SMN1; SMN2RARARARBRARG | |
| SCHEMBL27622903 | 0.79 | RARA (0.47) | HRH3SMN1; SMN2RARARARBRARG | |
| SCHEMBL2093689 | 0.79 | RARA (0.47) | HRH3SMN1; SMN2RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004212-A1 | Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-01-02 | — | — | US | claimed |
| EP-1251128-A1 | Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists | WARNER-LAMBERT COMPANY (US) | 2002-10-23 | — | — | EP | claimed |
| EP-1251128-B1 | Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists | WARNER LAMBERT CO (US) | 2006-12-06 | — | — | EP | disclosed |
| US-6828341-B2 | Brain disorders; anticonvulsants; central nervous system disorders; psychological disorders | WARNER-LAMBERT COMPANY | 2004-12-07 | — | — | US | disclosed |
| US-20030004212-A1 | Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1251128-A1 | Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists | WARNER-LAMBERT COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004212-A1 | Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists | GLRB, GRIN1, GRIN2B | HRH3 216/4885SMN1; SMN2 1067/4885RARA 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.